NBT Bank N.A. Purchases 11,040 Shares of Becton, Dickinson and Company $BDX

NBT Bank N.A. purchased a new stake in Becton, Dickinson and Company (NYSE:BDX) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 11,040 shares of the medical instruments supplier’s stock, valued at approximately $1,976,000.

Several other hedge funds have also recently bought and sold shares of the stock. TD Waterhouse Canada Inc. lifted its holdings in Becton, Dickinson and Company by 17.1% during the 2nd quarter. TD Waterhouse Canada Inc. now owns 96,211 shares of the medical instruments supplier’s stock valued at $14,715,000 after purchasing an additional 14,077 shares during the last quarter. Northside Capital Management LLC grew its stake in Becton, Dickinson and Company by 18.3% during the second quarter. Northside Capital Management LLC now owns 61,324 shares of the medical instruments supplier’s stock worth $9,280,000 after buying an additional 9,494 shares during the last quarter. NewEdge Advisors LLC grew its stake in Becton, Dickinson and Company by 35.0% during the first quarter. NewEdge Advisors LLC now owns 44,032 shares of the medical instruments supplier’s stock worth $6,923,000 after buying an additional 11,414 shares during the last quarter. Beverly Hills Private Wealth LLC bought a new stake in Becton, Dickinson and Company during the second quarter worth about $3,353,000. Finally, Wealthfront Advisers LLC acquired a new stake in shares of Becton, Dickinson and Company during the second quarter worth approximately $2,567,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on BDX shares. Weiss Ratings upgraded shares of Becton, Dickinson and Company from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, September 28th. Evercore set a $180.00 price target on Becton, Dickinson and Company in a research report on Monday, July 6th. Barclays assumed coverage on Becton, Dickinson and Company in a report on Wednesday, October 7th. They set an “underweight” rating and a $165.00 price target for the company. TD Cowen lifted their price objective on Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a research report on Wednesday, August 5th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $210.00 price objective on shares of Becton, Dickinson and Company in a research note on Thursday, August 6th. Eight research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $185.07.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP Roland Goette sold 2,438 shares of the company’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the transaction, the executive vice president owned 14,856 shares of the company’s stock, valued at approximately $2,686,559.04. This represents a 14.10% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Michael Feld sold 165 shares of the company’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total value of $31,100.85. Following the transaction, the executive vice president directly owned 19,720 shares in the company, valued at approximately $3,717,022.80. This represents a 0.83% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 6,906 shares of company stock worth $1,265,855 in the last quarter. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Trading Up 3.0%

BDX opened at $200.21 on Friday. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $200.47. The stock has a market capitalization of $55.16 billion, a PE ratio of 60.30, a PEG ratio of 13.10 and a beta of 0.21. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. The firm has a 50-day moving average price of $185.10 and a two-hundred day moving average price of $164.86.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same period in the prior year, the business earned $3.68 earnings per share. Becton, Dickinson and Company’s quarterly revenue was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, equities analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th were given a $1.05 dividend. This represents a $4.20 annualized dividend and a yield of 2.1%. The ex-dividend date was Wednesday, September 9th. Becton, Dickinson and Company’s payout ratio is 126.51%.

About Becton, Dickinson and Company

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.